The experimental vaccine against melanoma, announced by Moderna and Merck after passing a clinical trial, generates excitement in the medical community for its potential as a historic advancement, although caution is also expressed due to the lack of detailed data on its effectiveness. (translated)
La vacuna experimental del melanoma, entre la expectación por un posible avance histórico y la cautela por falta de datos
